Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen; Sanna-Kaisa Herukka; Niels Andreasen; Ines Baldeiras; Maria Bjerke; Kaj Blennow; Sebastiaan Engelborghs; Giovanni B. Frisoni; Tomasz Gabryelewicz; Samantha Galluzzi; Ron Handels; Milica G. Kramberger; Agnieszka Kulczynska; Jose Luis Molinuevo; Barbara Mroczko; Agneta Nordberg; Catarina Resende Oliveira; Markus Otto; Juha O. Rinne; Uros Rot; Esen Saka; Hilkka Soininen; Hanne Struyfs; Silvia Suardi; Pieter Jelle Visser; Bengt Winblad; Henrik Zetterberg; Gunhild Waldemar

doi:10.1016/j.jalz.2016.09.008

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B. Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G. Kramberger, Agnieszka Kulczynska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O. Rinne, Uros RotEsen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar^*

^*Corresponding author for this work

MHeNs - Cognitive Neuropsychiatry and Clinical Neuroscience

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebiospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support 4 recommendation to use CSF ADbiomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD bioniarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Original language	English
Pages (from-to)	274-284
Number of pages	11
Journal	Alzheimer's & Dementia
Volume	13
Issue number	3
DOIs	https://doi.org/10.1016/j.jalz.2016.09.008
Publication status	Published - Mar 2017

Keywords

Alzheiiner's disease
Biomarkers
CSF
Diagnosis
GRADE
Recommendations
ALZHEIMERS-DISEASE DIAGNOSIS
MILD COGNITIVE IMPAIRMENT
CEREBROSPINAL-FLUID TAU
COST-EFFECTIVENESS
PHOSPHORYLATED TAU
GRADING QUALITY
METAANALYSIS
GUIDELINES
MANAGEMENT
CRITERIA

Access to Document

10.1016/j.jalz.2016.09.008Licence: CC BY-NC-ND

Cite this

Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., Handels, R., Kramberger, M. G., Kulczynska, A., Luis Molinuevo, J., Mroczko, B., Nordberg, A., Oliveira, C. R., Otto, M., Rinne, J. O., ... Waldemar, G. (2017). Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's & Dementia, 13(3), 274-284. https://doi.org/10.1016/j.jalz.2016.09.008

@article{319557fa9da34aeb863737d5bb2dfc33,

title = "Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia",

abstract = "This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebiospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support 4 recommendation to use CSF ADbiomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD bioniarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.",

keywords = "Alzheiiner's disease, Biomarkers, CSF, Diagnosis, GRADE, Recommendations, ALZHEIMERS-DISEASE DIAGNOSIS, MILD COGNITIVE IMPAIRMENT, CEREBROSPINAL-FLUID TAU, COST-EFFECTIVENESS, PHOSPHORYLATED TAU, GRADING QUALITY, METAANALYSIS, GUIDELINES, MANAGEMENT, CRITERIA",

author = "Simonsen, {Anja Hviid} and Sanna-Kaisa Herukka and Niels Andreasen and Ines Baldeiras and Maria Bjerke and Kaj Blennow and Sebastiaan Engelborghs and Frisoni, {Giovanni B.} and Tomasz Gabryelewicz and Samantha Galluzzi and Ron Handels and Kramberger, {Milica G.} and Agnieszka Kulczynska and {Luis Molinuevo}, Jose and Barbara Mroczko and Agneta Nordberg and Oliveira, {Catarina Resende} and Markus Otto and Rinne, {Juha O.} and Uros Rot and Esen Saka and Hilkka Soininen and Hanne Struyfs and Silvia Suardi and Visser, {Pieter Jelle} and Bengt Winblad and Henrik Zetterberg and Gunhild Waldemar",

year = "2017",

month = mar,

doi = "10.1016/j.jalz.2016.09.008",

language = "English",

volume = "13",

pages = "274--284",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier Science",

number = "3",

}

Simonsen, AH, Herukka, S-K, Andreasen, N, Baldeiras, I, Bjerke, M, Blennow, K, Engelborghs, S, Frisoni, GB, Gabryelewicz, T, Galluzzi, S, Handels, R, Kramberger, MG, Kulczynska, A, Luis Molinuevo, J, Mroczko, B, Nordberg, A, Oliveira, CR, Otto, M, Rinne, JO, Rot, U, Saka, E, Soininen, H, Struyfs, H, Suardi, S, Visser, PJ, Winblad, B, Zetterberg, H & Waldemar, G 2017, 'Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia', Alzheimer's & Dementia, vol. 13, no. 3, pp. 274-284. https://doi.org/10.1016/j.jalz.2016.09.008

TY - JOUR

T1 - Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

AU - Simonsen, Anja Hviid

AU - Herukka, Sanna-Kaisa

AU - Andreasen, Niels

AU - Baldeiras, Ines

AU - Bjerke, Maria

AU - Blennow, Kaj

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni B.

AU - Gabryelewicz, Tomasz

AU - Galluzzi, Samantha

AU - Handels, Ron

AU - Kramberger, Milica G.

AU - Kulczynska, Agnieszka

AU - Luis Molinuevo, Jose

AU - Mroczko, Barbara

AU - Nordberg, Agneta

AU - Oliveira, Catarina Resende

AU - Otto, Markus

AU - Rinne, Juha O.

AU - Rot, Uros

AU - Saka, Esen

AU - Soininen, Hilkka

AU - Struyfs, Hanne

AU - Suardi, Silvia

AU - Visser, Pieter Jelle

AU - Winblad, Bengt

AU - Zetterberg, Henrik

AU - Waldemar, Gunhild

PY - 2017/3

Y1 - 2017/3

N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebiospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support 4 recommendation to use CSF ADbiomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD bioniarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebiospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support 4 recommendation to use CSF ADbiomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD bioniarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

KW - Alzheiiner's disease

KW - Biomarkers

KW - CSF

KW - Diagnosis

KW - GRADE

KW - Recommendations

KW - ALZHEIMERS-DISEASE DIAGNOSIS

KW - MILD COGNITIVE IMPAIRMENT

KW - CEREBROSPINAL-FLUID TAU

KW - COST-EFFECTIVENESS

KW - PHOSPHORYLATED TAU

KW - GRADING QUALITY

KW - METAANALYSIS

KW - GUIDELINES

KW - MANAGEMENT

KW - CRITERIA

U2 - 10.1016/j.jalz.2016.09.008

DO - 10.1016/j.jalz.2016.09.008

M3 - Article

C2 - 28341065

SN - 1552-5260

VL - 13

SP - 274

EP - 284

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 3

ER -